Fig. 5From: Low-dose nivolumab in advanced hepatocellular carcinomaComparison of progression-free survival (PFS) and overall survival (OS) according to viral hepatitis C RNA presentation. A PFS and (B) OS. SVR: sustained virological responseBack to article page